Current Status Not Enrolled Price Free Get Started Login to Enroll Start Course Global ASCVD Trends and Emerging Strategies Activity See More NAFLD/NASH and ASCVD Connection: Final Messages See More Combined Patient Management See More Patient Identification and Risk Stratification See More ASCVD and NAFLD/NASH: the Background of the Connection See More Part 4: Round table with the experts: Where do we stand in our battle against the ravages of diabetes? See More Parte 4, Mesa redonda com os especialistas – Onde estamos em nossa batalha contra os danos do diabetes? See More Parte 3, Sessão B – Opções terapêuticas para prevenção de doenças cardiovasculares See More Parte 3, Sessão A – Uma hierarquia de abordagens de tratamento com base na gravidade para o paciente DM2 com DCVA See More Parte 2 – Combatendo a aterosclerose: avaliando o risco CV para o paciente com DM2 See More Parte 1 – A história na batalha da insulina e glucagon See More Part 3 – Session B: Therapeutic options for prevention of cardiovascular disease See More Part 3 – Session A: A Hierarchy of Treatment Approaches based on Severity for the T2DM Patient with ASCVD See More Part 2: Combating Atherosclerosis: Assessing CV Patient Risk for the T2DM Patient See More Part 1: The History in the Battle of Insulin and Glucagon See More Modera resumen de los mensajes claves de las conferencias – Maria Cristina Izar (Brasil) See More Discusión Foro 4 – Panelist Roopa Mehta (Mexico) See More Nuevas terapias para la HF grave – Paola Varleta (Chile) See More Eficacia y seguridad de Lomitapida en HF homocigota – Dirk Blom (SudAfrica) See More Inhibidores PCSK9 en la HF grave – Maria Cristina Izar (Brasil) See More « ‹ › » page 1 / 13 Course Content Video 1 – Evidence of LDL-C as a Cause of Atherosclerotic Cardiovascular Disease Video 2 – The Sad and Inadequate Reality of Cholesterol Control Worldwide Video 3 – For ASCVD Prevention the Lower the LDL-C the Better Video 4 – Safety of Intensive LDL-C Reduction Video 5 – Impact of Blocking Circulating PCSK9 with Monoclonal Antibodies on Atherogenic Lipoproteins Video 6 – Impact of PCSK9 Inhibition in Very High-Risk Patients and How to Increase Cost Effectiveness Video 7 – Efficacy, Feasibility, and Safety of Early Use of Monoclonal PCSK9 Inhibitors after an Acute Coronary Syndrome Video 8 – Use of PCSK9 Inhibitors in Familial Hypercholesterolemia Patients Video 9 – Future Therapies for Dyslipidemia Treatment Global ASCVD Trends and Emerging Strategies Final Survey Course Content Video 1 – Evidence of LDL-C as a Cause of Atherosclerotic Cardiovascular Disease Video 2 – The Sad and Inadequate Reality of Cholesterol Control Worldwide Video 3 – For ASCVD Prevention the Lower the LDL-C the Better Video 4 – Safety of Intensive LDL-C Reduction Video 5 – Impact of Blocking Circulating PCSK9 with Monoclonal Antibodies on Atherogenic Lipoproteins Video 6 – Impact of PCSK9 Inhibition in Very High-Risk Patients and How to Increase Cost Effectiveness Video 7 – Efficacy, Feasibility, and Safety of Early Use of Monoclonal PCSK9 Inhibitors after an Acute Coronary Syndrome Video 8 – Use of PCSK9 Inhibitors in Familial Hypercholesterolemia Patients Video 9 – Future Therapies for Dyslipidemia Treatment Global ASCVD Trends and Emerging Strategies Final Survey
Part 4: Round table with the experts: Where do we stand in our battle against the ravages of diabetes? See More
Parte 4, Mesa redonda com os especialistas – Onde estamos em nossa batalha contra os danos do diabetes? See More
Parte 3, Sessão A – Uma hierarquia de abordagens de tratamento com base na gravidade para o paciente DM2 com DCVA See More
Part 3 – Session A: A Hierarchy of Treatment Approaches based on Severity for the T2DM Patient with ASCVD See More